Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma

Liver Transplantation

Volumn 10, Issue 10, 2004, Pages 1301-1311

  Kneteman, Norman M ^a,b   Oberholzer, José ^a   Al Saghier, Mohammed ^a   Meeberg, Glenda A ^a   Blitz, Maurice ^a   Ma, Mang M ^a   Wong, Winnie W S ^a   Gutfreund, Klaus ^a   Mason, Andrew L ^a   Jewell, Larry D ^a   Shapiro, A M James ^a   Bain, Vincent G ^a   Bigam, David L ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DACLIZUMAB; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEPATITIS B ANTIBODY; IRON; LAMIVUDINE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ABDOMINAL ABSCESS; ADULT; ANEMIA; ARTICLE; ASPIRATION PNEUMONIA; BACTEREMIA; BACTERIAL PNEUMONIA; BLOOD TRANSFUSION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEATH; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENITAL HERPES; GRAFT REJECTION; HEPATITIS B; HEPATITIS C; HERPES LABIALIS; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; IRON THERAPY; KAPLAN MEIER METHOD; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LUNG ASPERGILLOSIS; MALE; MONOTHERAPY; MOUTH ULCER; NEUTROPENIA; PATIENT SELECTION; PERITONITIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR VOLUME; WOUND INFECTION;

CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SIROLIMUS;

EID: 6444233347     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20237     Document Type: Article

References (33)

1. Ringe B, Pichlmayr R, Wittekind C, Tusch G. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991;15:270-285.
2. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993;218:145-151.
3. Dmitrewski J, EI-Gazzaz G, McMaster P. Hepatocellular cancer: resection or transplantation. J Hepatobiliary Pancreat Surg 1998;5:18-23.
4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
5. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-1403.
6. Vivarelli M, Bellusci R, Cucchetti A, Cavrini G, De Ruvo N, Aden AA, et al. Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation 2002;74:1746-1751.
7. Molmenti EP, Klintmalm GB. Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry. Liver Transpl 2002;8:736-748.
8. Bechstein WO, Guckelberger O, Kling N, Rayes N, Tullius SG, Lobeck H, et al. Recurrence-flee survival after liver transplantation for small hepatocellular carcinoma. Transpl Int 1998;11 (Suppl 1):S189-S192.
9. Klintmalm GB. Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg 1998;228:479-490.
10. Esnaola NF, Lauwers GY, Mirza NQ, Nagorney DM, Doherty D, Ikai I, et al. Predictors of microvascufar invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg 2002;6:224-232; discussion 232.
11. Yokoyama I, Carr B, Saitsu H, Iwatsuki S, Starzl TE. Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. Cancer 1991;68:2095-2100.
12. Mazzaferro V, Rondinara GF, Rossi G, Regalia E, De Carlis L, Cacamo L, et al. Milan multicenter experience in liver transplantation for hepatocellular carcinoma. Transplant Proc 1994; 26:3557-3560.
13. Majewski M, Korecka M, Kossev P, Li S, Goldman J, Moore J, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Nad Acad Sci USA 2000;97:4285-4290.
14. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000; 19:6680-6686.
15. Eng CP, Sehgal SN, Vezina C. Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot (Tokyo) 1984;37:1231-1237.
16. Schumacher G, Oidtmann M, Rosewicz S, Langrehr J, Jonas S, Mueller AR, et al. Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. Transplant Proc 2002;34:1392-1393.
17. Sobin LH, Wittekind CH. TNM classification of malignant tumours. New York: Wiley-Liss, Inc., 2002, 6th ed. pp. 81-83.
18. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatoceUular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002;8:765-774.
19. Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001;234:63-70.
20. Transcatheter arterial chemoembolizarion of hepatic tumors. Tecnologica MAP Suppl 2000;13-18.
21. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-442.
22. Farmer DG, Anselmo DM, Ghobrial RM, Yersiz H, McDiarmid SV, Cao C, et al. Liver transplantation for fulminant hepatic failure: experience with more than 200 patients over a 17-year period. Ann Surg 2003;237:666-675; discussion 675-666.
23. Brattstrom C, Wilczek H, Tyden G, Bottiger Y, Sawe J, Groth CG. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 1998;65:1272-1274.
24. Watson CJ, Friend PJ, Jamieson NV, Frick TW, Alexander G, Gimson AE, et al. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 1999;67:505-509.
25. Hong JC, Kahan BD. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation 2000;69:2085-2090.
26. Ryan EA, Lakey JR, Rajotte RV, Kothutt GS, Kin T, Imes S, et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 2001;50:710-719.
27. McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, MacDonald AS. Sirolimus-tacrolimus combination immunosuppression [letter]. Lancet 2000;355:376-377.
28. Freise CE, Ferrell L, Liu T, Ascher NL, Roberts JP. Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma. Transplantation 1999;67:510-513.
29. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999;397:530-534.
30. Nabel GJ. A transformed view of cyclosporine. Nature 1999; 397:471-472.
31. Guba M, yon Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-135.
32. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971;133: 275-288.
33. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29(6 Suppl 16):15-18.